S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS

• N. G. Daver,
• P. Vyas,
• S. Kambhampati,
• M. M. Al Malki,
• R. Larson,
• A. Asch,
• G. Mannis,
• W. Chai-Ho,
• T. Tanaka,
• T. Bradley,
• D. Jeyakumar,
• E. Wang,
• G. Xing,
• M. Chao,
• G. Ramsingh,
• C. Renard,
• I. Lal,
• J. Zeidner,
• D. Sallman

Affiliations

N. G. Daver

1 The University of Texas MD Anderson Cancer Center, Houston, United States of America

P. Vyas

2 University of Oxford, Oxford, United Kingdom

S. Kambhampati

3 Healthcare Midwest, Kansas City

M. M. Al Malki

4 City of Hope National Medical Center, Duarte

R. Larson

5 University of Chicago, Chicago

A. Asch

6 University of Oklahoma, Oklahoma City

G. Mannis

7 Stanford University, Stanford

W. Chai-Ho

8 University of California Los Angeles, Los Angeles

T. Tanaka

9 University of California San Diego, San Diego

T. Bradley

10 University of Miami, Miami

D. Jeyakumar

11 University of California Irvin, Irvine

E. Wang

12 Roswell Park Comprehensive Cancer Center, Buffalo

G. Xing

13 Gilead Sciences, Inc., Foster City

M. Chao

13 Gilead Sciences, Inc., Foster City

G. Ramsingh

13 Gilead Sciences, Inc., Foster City

C. Renard

13 Gilead Sciences, Inc., Foster City

I. Lal

13 Gilead Sciences, Inc., Foster City

J. Zeidner

14 Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill

D. Sallman

15 Moffitt Cancer Center, Tampa, United States of America